HIV Infections
Conditions
Keywords
Raltegravir, efficacy, safety, raltegravir-containing regimens, HIV urban clinic setting
Brief summary
This will be a retrospective analysis of efficacy, safety and tolerability of raltegravir as part of an optimized therapy in a clinical setting. Follow-up is calculated from the treatment initiation (with or without raltegravir) up to the date of discontinuation of the considered regimen or the date of last visit or the date of lost to follow-up, whichever came first. The Aim of the study is to evaluate the efficacy and safety of raltegravir-containing regimens in a urban clinic setting.
Interventions
None listed
Sponsors
Ospedale San Raffaele
Università Vita-Salute San Raffaele
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Subjects who received raltegravir and were previously exposed to NRTIs, NNRTIs, PIs, regardless of the stage of HIV disease at the start of the treatment.
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Real-Life | baseline and week 48 | Primary endpoint is the proportion of patients with HIV-1 RNA\<50 copies/ml at weeks 48 after treatment initiation (baseline). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Real-Life | baseline and week 48 | Secondary endpoints are: * Proportion of patients with HIV-1 RNA\<50 copies/ml at the end of the treatment/last available visit * Proportion of patients with HIV-1 RNA\<400 copies/ml at week 48 * Increase in absolute CD4 cell count from baseline * Frequency of side effects associated with raltegravir treatment * Frequency of reasons for starting/stopping raltegravir treatment |
Countries
Italy
Outcome results
None listed